HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

<ul>
<li>Although DeepSeek's continuous updates, iterations, and deep integration with more and more healthcare enterprises in China will bring positive market sentiment, we have seen certain limitations and even risks behind.</li>
<li>Currently, AI healthcare relies heavily on government subsidies or hardware sales in China, which lacks sustainable payment scenarios and profit model. The data security/privacy/compliance issue may not be completely solve.</li>
<li>For the companies that have integrated with DeepSeek, investors need to verify their afterwards financial performance and fundamentals. If it does not meet expectations, investors are recommended sell in time.</li>
</ul>


Although DeepSeek's continuous updates, iterations, and deep integration with more and more healthcare enterprises in China will bring positive market sentiment, we have seen certain limitations and even risks behind.
Currently, AI healthcare relies heavily on government subsidies or hardware sales in China, which lacks sustainable payment scenarios and profit model. The data security/privacy/compliance issue may not be completely solve.
For the companies that have integrated with DeepSeek, investors need to verify their afterwards financial performance and fundamentals. If it does not meet expectations, investors are recommended sell in time.


DeekSeek May Not Be The "Game Changer" In China Healthcare - Time to Be Rational

Podcast by Joe Weisenthal & Tracy Alloway, Odd Lots

Odd Lots

Podcast by Joe Weisenthal & Tracy Alloway

Bloomberg's Joe Weisenthal and Tracy Alloway explore the most interesting topics in finance, markets and economics. Join the conversation every Monday and Thursday.

<ul><li>Odd Lots podcast announces live show in Washington D.C. discussing the Jones Act and other topics</li><li>Tim Opler from Ste discusses China's role in the pharmaceutical supply chain on the podcast</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.</em></p>

Odd Lots podcast announces live show in Washington D.C. discussing the Jones Act and other topicsTim Opler from Ste discusses China's role in the pharmaceutical supply chain on the podcastThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.

Here Comes the Booming Chinese Biotech Sector

Equity Capital Markets

WeDoctor Holdings / Equity Capital Markets

<ul>
<li>We Doctor's business structure has undergone significant changes. Its positioning has become the AI-enabled healthcare solutions provider. The current business model of We Doctor is To G (To Government) model.</li>
<li>Whether We Doctor can replicate Tianjin model in other cities is uncertain because it may not have deep connections/resources in new cities/regions. Profit model of AI+ healthcare isn’t yet clear.</li>
<li>We Doctor's Pre-IPO valuation has reached US$6.7 billion, which is too expensive. Reasonable valuation could be just US$1-2 billion, and should be lower than Ping An Good Doctor.</li>
</ul>


We Doctor's business structure has undergone significant changes. Its positioning has become the AI-enabled healthcare solutions provider. The current business model of We Doctor is To G (To Government) model.
Whether We Doctor can replicate Tianjin model in other cities is uncertain because it may not have deep connections/resources in new cities/regions. Profit model of AI+ healthcare isn’t yet clear.
We Doctor's Pre-IPO valuation has reached US$6.7 billion, which is too expensive. Reasonable valuation could be just US$1-2 billion, and should be lower than Ping An Good Doctor.


Pre-IPO We Doctor Holdings - The Good Story of AI May Not Turn Things Around

Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

<ul>
<li>According to PHIP and Crunchbase, We Doctor’s most recently reported valuation was a ~$411M Series F led by HongShan Capital and Millennium Management at a ~$6.7B post-money valuation.  </li>
<li>My ballpark estimates suggest that IPO valuation target may be below last round valuation. However, I do not expect a significant discount to Series F post-money valuation of ~$6.7B.</li>
<li>I think investors will ask what is the revenue growth trajectory ahead (FY25-FY28) and why gross profit margins can’t be higher? What is the path to positive free cash flow?</li>
</ul>


According to PHIP and Crunchbase, We Doctor’s most recently reported valuation was a ~$411M Series F led by HongShan Capital and Millennium Management at a ~$6.7B post-money valuation.  
My ballpark estimates suggest that IPO valuation target may be below last round valuation. However, I do not expect a significant discount to Series F post-money valuation of ~$6.7B.
I think investors will ask what is the revenue growth trajectory ahead (FY25-FY28) and why gross profit margins can’t be higher? What is the path to positive free cash flow?


We Doctor Holdings IPO: Some Thoughts on IPO Valuation Target Ahead of the Offering

<ul>
<li>We Doctor Holdings, a top-tier provider of AI-enabled medical services and digital platform which connects hospitals, doctors, and pharmacies, plans to go public in Hong Kong.</li>
<li>We Doctor Holdings has raised ~$1.5B to date from investors, including Tencent, 5Y Capital, Goldman Sachs, Hillhouse Capital, AIA, and Qiming Venture Partners, among others.</li>
<li>The Hangzhou-based healthtech company has delivered explosive revenue growth of 107% y/y for the six months ended Jun-24.  </li>
</ul>


We Doctor Holdings, a top-tier provider of AI-enabled medical services and digital platform which connects hospitals, doctors, and pharmacies, plans to go public in Hong Kong.
We Doctor Holdings has raised ~$1.5B to date from investors, including Tencent, 5Y Capital, Goldman Sachs, Hillhouse Capital, AIA, and Qiming Venture Partners, among others.
The Hangzhou-based healthtech company has delivered explosive revenue growth of 107% y/y for the six months ended Jun-24.  


We Doctor Holdings IPO Preview: Explosive Growth and Narrowing Losses, The Right Time for an IPO

China

Ping An Healthcare and Technology Company Limited provides health care software solutions. The Company offers mobile platform for online consultation, hospital referral and appointment, health management, and wellness interaction services, as well as connects consumers and patients with health care resources. Ping An Healthcare and Technology serves customers in China.

Ping An Healthcare and Technology (1833 HK)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ping An Healthcare and Technology (1833 HK)

DeekSeek May Not Be The "Game Changer" In China Healthcare - Time to Be Rational

DeepSeek's integration with companies brings market optimism, but risks remain due to unsustainable profit model and data security...

Xinyao (Criss) Wang

Here Comes the Booming Chinese Biotech Sector

Odd Lots podcast announces live show in Washington D.C. discussing the Jones Act and other topics Tim Opler from Ste discusses China's role in the...

Odd Lots

Pre-IPO We Doctor Holdings - The Good Story of AI May Not Turn Things Around

We Doctor shifts to AI medical solution provider with To G model, facing uncertainty in replicating Tianjin model nationwide.Pre-IPO valuation at...

Xinyao (Criss) Wang

We Doctor Holdings IPO: Some Thoughts on IPO Valuation Target Ahead of the Offering

In my insight, I discuss expectations from upcoming We Doctor Holdings IPO and provide some thoughts on IPO valuation target ahead of the offering...

Andrei Zakharov

We Doctor Holdings IPO Preview: Explosive Growth and Narrowing Losses, The Right Time for an IPO

We Doctor, a Tencent-backed online healthcare platform and provider of AI-enabled medical services in China, has refiled PHIP to proceed with up to...

Andrei Zakharov

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

DeekSeek May Not Be The "Game Changer" In China Healthcare - Time to Be Rational

​DeepSeek's integration with companies brings market optimism, but risks remain due to unsustainable profit model and data security...

Xinyao (Criss) Wang

Here Comes the Booming Chinese Biotech Sector

Odd Lots podcast announces live show in Washington D.C. discussing the Jones Act and other topics Tim Opler from Ste discusses China's role in the...

Odd Lots

Pre-IPO We Doctor Holdings - The Good Story of AI May Not Turn Things Around

​We Doctor shifts to AI medical solution provider with To G model, facing uncertainty in replicating Tianjin model nationwide.Pre-IPO valuation at...

Xinyao (Criss) Wang

We Doctor Holdings IPO: Some Thoughts on IPO Valuation Target Ahead of the Offering

In my insight, I discuss expectations from upcoming We Doctor Holdings IPO and provide some thoughts on IPO valuation target ahead of the offering...

Andrei Zakharov

We Doctor Holdings IPO Preview: Explosive Growth and Narrowing Losses, The Right Time for an IPO

We Doctor, a Tencent-backed online healthcare platform and provider of AI-enabled medical services in China, has refiled PHIP to proceed with up to...

Andrei Zakharov

DeepSeek's integration with companies brings market optimism, but risks remain due to unsustainable profit model and data security...

We Doctor shifts to AI medical solution provider with To G model, facing uncertainty in replicating Tianjin model nationwide.Pre-IPO valuation at...